Abstract
Background and Aims : Chronic kidney disease (CKD) patients present increased cardiovascular (CV) morbidity and mortality, with atherosclerosis being the underlying phenomenon in most of CV events. Clinical trials and metanalyses have linked administration of pentoxifylline (PTX) with renoprotection secondary to anti-inflammatory and antifibrotic effects in CKD patients, together with increased levels of the anti-aging protein Klotho. However, the effect of PTX on atherosclerosis in CKD patients has not been analysed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
